44 related articles for article (PubMed ID: 11046101)
1. Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding.
Maillard MP; Rossat J; Brunner HR; Burnier M
J Pharmacol Exp Ther; 2000 Nov; 295(2):649-54. PubMed ID: 11046101
[TBL] [Abstract][Full Text] [Related]
2. Metabolites of the angiotensin II antagonist tasosartan: the importance of a second acidic group.
Ellingboe JW; Collini MD; Quagliato D; Chen J; Antane M; Schmid J; Hartupee D; White V; Park CH; Tanikella T; Bagli JF
J Med Chem; 1998 Oct; 41(22):4251-60. PubMed ID: 9784100
[TBL] [Abstract][Full Text] [Related]
3. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors.
Rehman A; Rahman AR; Rasool AH
J Hum Hypertens; 2002 Apr; 16(4):261-6. PubMed ID: 11967720
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist--characterization by use of Schild regression technique in man.
Breithaupt-Grögler K; Malerczyk C; Belz GG; Butzer R; Herrmann V; Stass H; Wensing G
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):434-41. PubMed ID: 9352392
[TBL] [Abstract][Full Text] [Related]
5. Peripheral administration of AT1 receptor blockers and pressor responses to central angiotensin II and sodium.
Zhang J; Leenen FH
Can J Physiol Pharmacol; 2001 Oct; 79(10):861-7. PubMed ID: 11697745
[TBL] [Abstract][Full Text] [Related]
6. Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings: a placebo-controlled study in healthy volunteers.
Gossmann J; Burkhardt R; Harder S; Lenz T; Sedlmeyer A; Klinkhardt U; Haak T; Geiger H; Scheuermann EH
Clin Pharmacol Ther; 2000 Nov; 68(5):501-9. PubMed ID: 11103753
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension.
Andrawis NS; Battle MM; Klamerus KJ; Burghart PH; Neefe L; Weinryb I; Mayer P; Abernethy DR
J Clin Pharmacol; 2000 Mar; 40(3):231-41. PubMed ID: 10709151
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
[TBL] [Abstract][Full Text] [Related]
9. Effects of angiotensin antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients.
Rhéaume C; Waib PH; Lacourcière Y; Cléroux J
J Hypertens; 1998 Dec; 16(12 Pt 2):2085-9. PubMed ID: 9886901
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study. Tasosartan Investigators Group.
Neutel JM; Buckalew V; Chrysant SG; Mroczek WJ; Ruff DA; Weber M
Am Heart J; 1999 Jan; 137(1):118-25. PubMed ID: 9878944
[TBL] [Abstract][Full Text] [Related]
11. The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein beta3 subunit (GNB3) C825T polymorphism.
Mitchell A; Rushentsova U; Siffert W; Philipp T; Wenzel RR
Clin Pharmacol Ther; 2006 Mar; 79(3):274-81. PubMed ID: 16513451
[TBL] [Abstract][Full Text] [Related]
12. Effect of the non peptide angiotensin II antagonist, GR117289C on the vasoconstrictor actions of angiotensin II in the human forearm.
Lyons D; Webster J; Nixon A; Young MM; Smith J; Benjamin N
Br J Clin Pharmacol; 1997 Mar; 43(3):323-6. PubMed ID: 9088589
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-receptor expression and IP3 receptor and PKCepsilon proteins.
Xu Y; Menon V; Jugdutt BI
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):184-95. PubMed ID: 11967812
[TBL] [Abstract][Full Text] [Related]
14. Blockade of angiotensin II type-1 receptor increases salt sensitivity in Sprague-Dawley rats.
Endo S; Mori T; Yoneki Y; Nakamichi T; Hosoya T; Ogawa S; Tokudome G; Hosoya T; Miyata T; Ito S
Hypertens Res; 2009 Jun; 32(6):513-9. PubMed ID: 19407824
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects.
Latif F; Tandon S; Obeleniene R; Hankins SR; Berlowitz MS; Ennezat PV; Le Jemtel TH
J Card Fail; 2001 Sep; 7(3):265-8. PubMed ID: 11561228
[TBL] [Abstract][Full Text] [Related]
16. Intranasal angiotensin II in humans reduces blood pressure when angiotensin II type 1 receptors are blocked.
Derad I; Sayk F; Lehnert H; Marshall L; Born J; Nitschke M
Hypertension; 2014 Apr; 63(4):762-7. PubMed ID: 24420549
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo.
Barki-Harrington L; Luttrell LM; Rockman HA
Circulation; 2003 Sep; 108(13):1611-8. PubMed ID: 12963634
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II type 2 receptor provides an endogenous brake during inflammation-induced microvascular fluid leak.
Ereso AQ; Ramirez RM; Sadjadi J; Cripps MW; Cureton EL; Curran B; Victorino GP
J Am Coll Surg; 2007 Oct; 205(4):527-33. PubMed ID: 17903725
[TBL] [Abstract][Full Text] [Related]
19. Renin-angiotensin blockade improves renal cGMP production via non-AT(2)-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat.
Uhlenius N; Vuolteenaho O; Tikkanen I
J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):233-9. PubMed ID: 11881129
[TBL] [Abstract][Full Text] [Related]
20. Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.
Maillard MP; Mazzolai L; Daven V; Centeno C; Nussberger J; Brunner HR; Burnier M
Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1201-8. PubMed ID: 10619583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
